期刊文献+

肠促胰岛素用于2型糖尿病治疗的研究进展 被引量:3

下载PDF
导出
摘要 肠促胰岛素如抑胃多肽(GIP)和胰高血糖素样肽1(GLP1)可以调节β细胞增殖和细胞防御,在β细胞刺激的胰岛素分泌上发挥重要作用。GLP1可抑制胃排空、分泌和食物摄入,运用于2型糖尿病患者可明显降低餐后血糖,且发生低血糖风险小,尤其适用于老年糖尿病患者。天然GLP1在体内迅速被DPPIV降解,目前已有抗降解、长效的GLP1R配体用于临床研究。DPPIV抑制剂可以发挥降糖作用。
作者 柳岚 雷闽湘
出处 《国外医学(生理病理科学与临床分册)》 2005年第3期223-226,共4页 Foreign Medical Sciences(Pathophysiology and Clinical Medicine)
  • 相关文献

参考文献22

  • 1Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagons-like peptide-1 in obese type 2 diabetic patients and healthy subjects[J]. J Clin Endocrinol Metab, 2003,88(2):220-224.
  • 2Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1 )-cells[J]. J Endocrinol,2002,174(2) : 233-246.
  • 3Lewis JT, Dayanandan B, Habener JF, et al. Glucose-depentent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist [J].Endocrinology, 2000,141 (10) :3710-3716.
  • 4Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity [J]. Nat Med, 2002,8(3) :738-742.
  • 5Hinke SA, Gelling RW, Pederson RA, et al. Dipeptidyl peptidaseⅣ-resistant [ D-Ala(2) ] glucose- dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats[J]. Diabetes, 2002,51 (3) :652-661.
  • 6Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes [J]. Diabetes Care, 2003,26 (10) :2929-2940.
  • 7Kim JG, Baggio LL, Bridon DP, et al. Development and characterization of a GLP-l-albumin conjugate which retains the ability to activate the GLP-I receptor in vivo [J]. Diabetes, 2003,52 (3) : 751-759.
  • 8Wang Q, Brubaker PL. Glucagon-like peptide-I treatment delays the onset of diabetes in 8 week-old db/db mice [J]. Diabetologia, 2002,45 (10) : 1263-1273.
  • 9Kjems LL, Hoist JJ, Volund A, et al. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects [J]. Diabetes, 2003,52 (2) : 380-386.
  • 10Zander M, Taskiran M, Toft-Nielsen MB, et al. Additive glucoselowering effects of glucagons-like peptide-I and metformin in type 2 diabetes[J]. Diabetes Care,2001,24(4) :720-725.

同被引文献18

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部